immunitoAI
immunitoAI is a Bengaluru-based TechBio company that uses generative AI to design novel antibody therapeutics de novo, serving pharmaceutical and biotechnology customers through enterprise discovery partnerships and an internal proprietary drug pipeline.
- Company typePrivate
- Founded2020
- HeadquartersBengaluru, India
- Headcount11–50
- GTM typeB2B
- OfferingServices
What immunitoAI does
immunitoAI is a Bengaluru-based TechBio company founded in 2020 that builds generative AI systems for de novo antibody design, serving pharmaceutical and biotechnology companies as its primary customer segment. Its proprietary platform uses deep neural networks trained on the structural complementarity between antibody paratopes and antigen epitopes to design antibody sequences computationally rather than via animal immunization, and to embed drug developability properties (stability, affinity, specificity) at the design stage. The company states a reduction in discovery timelines from the industry-standard 4-5 years to approximately 11-12 months.
The technology stack is paired with an in-house biological validation laboratory at C-CAMP in Bengaluru, where AI-designed sequences are synthesized and characterized, with experimental data feeding back into model training. Core products comprise an AI-powered antibody discovery platform and AI-generated novel antibody therapeutic candidates. The company has publicly emphasized three pillars: Design over Discovery (in silico generation without biological sources), Drug-First Antibodies (pre-defined developability properties), and a Structure-First AI Platform (shape-complementarity neural networks).
The business model is B2B enterprise: immunitoAI sells antibody discovery and screening services to pharma R&D and business development teams through direct field sales, multi-year contracts, and partnership agreements, with no public pricing disclosed. Following a $6.1M Series A in November 2025 led by Ashish Kacholia, the company has signaled a strategic shift toward building an internal proprietary antibody pipeline alongside its service offering. Total disclosed funding to date is approximately $7.54M across pre-seed, seed and Series A rounds, and the company maintains 11-50 employees across R&D, engineering and lab functions.
immunitoAI firmographics
Firmographics- Name
- immunitoAI
- Legal name
- immunitoAI Private Limited
- Website
- https://immunitoai.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- immunitoAI is a Bengaluru-based TechBio company that uses generative AI to design novel antibody therapeutics de novo, serving pharmaceutical and biotechnology customers through enterprise discovery partnerships and an internal proprietary drug pipeline.
- Ownership category
- akta.pro rank
immunitoAI industry classification
Industry- Product category
- AI-driven Antibody Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where immunitoAI is headquartered
LocationHeadquarters
- HQ city
- Bengaluru
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
immunitoAI business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- AI-driven Antibody Discovery Services: immunitoAI provides AI-powered antibody discovery and screening services to pharmaceutical and biotech companies. The company designs and identifies antibodies for specific protein targets using its proprietary AI platform, then validates candidates through in-house biological methods. Revenue is generated through service contracts and potentially through the development of proprietary antibody candidates.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise contracts for pharmaceutical companies |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
immunitoAI product offering
Product offeringCore offering
immunitoAI develops and provides an AI-driven antibody discovery service that uses proprietary generative AI neural networks to design novel antibody therapeutics from scratch, without relying on animal or human biological sources. The platform embeds pre-defined drug properties (stability, affinity, specificity, developability) at the design inception and validates candidates through an in-house biological laboratory at C-CAMP, Bengaluru. The service targets pharmaceutical and biotech companies seeking faster, more efficient antibody discovery compared to conventional 4-5 year timelines.
Product overview
immunitoAI operates as a TechBio company with a single unified product offering: an AI-powered antibody discovery platform that generates novel antibody therapeutics from scratch. The platform is powered by proprietary generative AI neural networks trained on structural complementarity between antibodies and antigens. The core platform designs antibodies with pre-defined drug characteristics, which are then synthesized, characterized, and validated in the company's in-house biological laboratory. The platform rests on three foundational pillars: Design over Discovery (de novo antibody design without biological sources), Drug-First Antibodies (pre-defined drug properties embedded at inception), and Structure-First AI Platform (neural networks trained on shape complementarity). This integrated computational-biological approach aims to reduce antibody development time from 4-5 years to 11-12 months.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-Powered Antibody Discovery Platform immunitoAI's proprietary generative AI platform that designs novel antibodies and antibody fragments from scratch using deep neural networks trained on structural complementarity between antibody paratopes and antigen epitopes. The platform is offered to pharmaceutical and biotech companies as an antibody discovery service with in-house biological validation of generated candidates.
- AI-Generated Novel Antibody Therapeutics Therapeutic antibody candidates generated by immunitoAI's AI platform with pre-defined drug properties (stability, affinity, specificity, developability) embedded at the design inception. Antibodies are designed for specific protein targets including oncology and autoimmune disease indications and validated through in-house biological methods as part of the company's drug pipeline.
Quantifiable outcome
- Reduces antibody development timeline from 4-5 years to 11-12 months
- +3 more outcomes
Companies that use immunitoAI
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
immunitoAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
immunitoAI partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered supporting and core.
- TiE Global Summit 2024supportingAs a MeitY-supported startup, immunitoAI showcased its AI-powered antibody drug discovery platform at TiE Global Summit 2024 among 3,000+ attendees including investors, industry leaders, and enthusiasts.
- NASSCOM GenAI FoundrysupportingimmunitoAI was selected for NASSCOM GenAI Foundry's second cohort, participating in an intensive two-day bootcamp covering AI development aspects and connecting with industry experts.
- Google for Startups AcceleratorsupportingimmunitoAI was selected as one of 20 AI-first startups from 720+ applicants for Google for Startups Accelerator India Class 8. The four-month program provided mentorship, investor access, technical support, and concluded with Demo Day on April 5th, 2024.
- Centre for Cellular and Molecular Platforms (C-CAMP)coreimmunitoAI's biological laboratory is incubated at C-CAMP in Bengaluru. The company participates in C-CAMP events and programs including Sugar Rush with Science talks and MeitY-supported programs through the C-CAMP DigitalTechSolutions cohort.
Scale indicators5 records
Recent moves4 records
Expansion highlights5 records
immunitoAI competitors and assessment
Company assessmentOthers
- AbCellera Biologics (Note: already listed): Placeholder not used.
Direct peers
- AbCellera Biologics: AbCellera operates an AI-powered antibody discovery platform that partners with pharma to identify lead candidates from immune repertoires, directly competing with immunitoAI's AI antibody design services for pharma customers.
- Absci: Absci combines generative AI with a wet-lab platform for de novo antibody design, the closest direct analog to immunitoAI's drug-first, structure-first approach to therapeutic antibody creation.
- Generate Biomedicines: Generate Biomedicines uses generative AI to program novel protein therapeutics from scratch, directly competing with immunitoAI in de novo antibody and protein design for pharma partners.
- BigHat Biosciences: BigHat Biosciences designs antibodies using ML integrated with a high-throughput wet lab, closely mirroring immunitoAI's structure-first AI platform combined with in-house biological validation.
- Cradle Bio: Cradle applies generative AI and ML to protein engineering across modalities, overlapping with immunitoAI's AI-driven antibody and therapeutic protein design capabilities.
- Antiverse: Antiverse uses AI/ML for antibody design with a focus on difficult targets, comparable to immunitoAI's structure-first approach aimed at previously undruggable antigens.
Broad incumbents
- Isomorphic Labs: Alphabet's Isomorphic Labs applies DeepMind's protein-structure AI to drug discovery broadly, including antibody design, and is a well-capitalized incumbent in the same AI-first biologics space as immunitoAI.
Regional players
- Aragen Life Sciences: India-headquartered CRO/CDMO offering antibody discovery and development services, geographically adjacent and thematically comparable to immunitoAI as a Bengaluru-based biologics services platform.
- Syngene International: India-based CRO with biologics discovery capabilities including antibody work, comparable to immunitoAI as a domestic Indian provider of antibody-related services to global pharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
immunitoAI social profiles
Digital presenceimmunitoAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
immunitoAI leadership team
Management profileNumber of profiles
Profiles11 records
immunitoAI funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
immunitoAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about immunitoAI
What does immunitoAI do?
immunitoAI develops and provides an AI-driven antibody discovery service that uses proprietary generative AI neural networks to design novel antibody therapeutics from scratch, without relying on animal or human biological sources. The platform embeds pre-defined drug properties (stability, affinity, specificity, developability) at the design inception and validates candidates through an in-house biological laboratory at C-CAMP, Bengaluru. The service targets pharmaceutical and biotech companies seeking faster, more efficient antibody discovery compared to conventional 4-5 year timelines.
Is immunitoAI a public or private company?
immunitoAI is a private company. It is classified as venture growth investor backed and is currently operating.
When was immunitoAI founded?
immunitoAI was founded in 2020. It employs 11 to 50 people.
Where is immunitoAI based?
immunitoAI is headquartered in Bengaluru, India, in the Asia region.
How does immunitoAI make money?
One revenue line is on record: AI-driven Antibody Discovery Services.
Who are immunitoAI's main competitors?
AbCellera Biologics (Note: already listed) is listed as an others. Direct peers are AbCellera Biologics, Absci, Generate Biomedicines, BigHat Biosciences, Cradle Bio and Antiverse. Isomorphic Labs is listed as a broad incumbent. Regional players are Aragen Life Sciences and Syngene International.
Does immunitoAI have an API?
No public API is recorded for immunitoAI.
What industry is immunitoAI in?
immunitoAI's product category is AI-driven Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.